antiplatelet therapy

Drugmaker recalls samples of antiplatelet drugAstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
FDA expands Brilinta approval for long-term use in patients with heart attack historyFDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.
Dual antiplatelet therapy lowers risk of CV death in MI secondary preventionSecondary prevention of MI still calls for a careful balancing act between risks and benefits.
NSAIDs increase bleeding risk in patients taking anticoagulantsA Danish study of 150,900 patients found that the risk of serious bleeding doubled when patients were treated with NSAIDs.
FDA reviews trial results of long-term dual antiplatelet therapyFDA announced that it will review results from a clinical trial showing that long-term dual antiplatelet therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment.
FDA approves clot-busting vorapaxarFDA approved vorapaxar (Zontivity, Merck Sharp & Dohme Corp., a subsidiary of Merck) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs.
How long should antiplatelet therapy last following stent implantation?Short-term dual antiplatelet therapy was as effective as long-term therapy for patients who underwent percutaneous coronary intervention (PCI) with a second-generation drug-eluting stent, according to an online study published in JAMA.